<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d2 20140930//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?DTDIdentifier.IdentifierValue -//ES//DTD journal article DTD version 5.2.0//EN//XML?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName art520.dtd?><?SourceDTD.Version 5.2.0?><?ConverterInfo.XSLTName elsevier2nlmx2.xsl?><?ConverterInfo.Version 2?><?origin publisher?><?FILEmeta_CELREP1265 xml ?><?FILEmain xml ?><?FILEmain pdf ?><?FILEgr1 jpg ?><?FILEgr2 jpg ?><?FILEgr3 jpg ?><?FILEgr4 jpg ?><?FILEgr5 jpg ?><?FILEgr6 jpg ?><?FILEfx1 jpg ?><?FILEmmc1 pdf ?><?FILEmmc2 pdf ?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cell Rep</journal-id><journal-id journal-id-type="iso-abbrev">Cell Rep</journal-id><journal-title-group><journal-title>Cell Reports</journal-title></journal-title-group><issn pub-type="epub">2211-1247</issn><publisher><publisher-name>Cell Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4536294</article-id><article-id pub-id-type="publisher-id">S2211-1247(14)00738-4</article-id><article-id pub-id-type="doi">10.1016/j.celrep.2014.08.062</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Rewiring of an Epithelial Differentiation Factor, miR-203, to Inhibit Human Squamous Cell Carcinoma Metastasis</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Benaich</surname><given-names>Nathan</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref><xref rid="fn1" ref-type="fn">4</xref></contrib><contrib contrib-type="author"><name><surname>Woodhouse</surname><given-names>Samuel</given-names></name><xref rid="aff2" ref-type="aff">2</xref><xref rid="fn1" ref-type="fn">4</xref></contrib><contrib contrib-type="author"><name><surname>Goldie</surname><given-names>Stephen&#x000a0;J.</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Mishra</surname><given-names>Ajay</given-names></name><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Quist</surname><given-names>Sven&#x000a0;R.</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Watt</surname><given-names>Fiona&#x000a0;M.</given-names></name><email>fiona.watt@kcl.ac.uk</email><xref rid="aff2" ref-type="aff">2</xref><xref rid="cor1" ref-type="corresp">&#x02217;</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE, UK</aff><aff id="aff2"><label>2</label>Centre for Stem Cells and Regenerative Medicine, King&#x02019;s College London, 28<sup>th</sup> Floor, Tower Wing, Guy&#x02019;s Hospital, Great Maze Pond, London SE1 9RT, UK</aff><aff id="aff3"><label>3</label>Clinic of Dermatology and Venereology, Otto-von-Guericke University, Magdeburg, Leipziger Strasse 44, 39120 Magdeburg, Germany</aff><author-notes><corresp id="cor1"><label>&#x02217;</label>Corresponding author <email>fiona.watt@kcl.ac.uk</email></corresp><fn id="fn1"><label>4</label><p>Co-first author</p></fn></author-notes><pub-date pub-type="pmc-release"><day>02</day><month>10</month><year>2014</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date						pub-type="epub">.--><pub-date pub-type="collection"><day>09</day><month>10</month><year>2014</year></pub-date><pub-date pub-type="epub"><day>02</day><month>10</month><year>2014</year></pub-date><volume>9</volume><issue>1</issue><fpage>104</fpage><lpage>117</lpage><history><date date-type="received"><day>19</day><month>9</month><year>2013</year></date><date date-type="rev-recd"><day>5</day><month>8</month><year>2014</year></date><date date-type="accepted"><day>25</day><month>8</month><year>2014</year></date></history><permissions><copyright-statement>&#x000a9; 2014 The Authors</copyright-statement><copyright-year>2014</copyright-year><license license-type="CC BY" xlink:href="http://creativecommons.org/licenses/by/3.0/"><license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).</license-p></license></permissions><abstract><title>Summary</title><p>Metastatic colonization of distant organs underpins&#x000a0;the majority of human-cancer-related deaths, including deaths from head and neck squamous cell carcinoma (HNSCC). We report that miR-203, a miRNA that triggers differentiation in multilayered epithelia, inhibits multiple postextravasation events during HNSCC lung metastasis. Inducible reactivation of miR-203 in already established lung metastases reduces the overall metastatic burden. Using an&#x000a0;integrated approach, we reveal that miR-203 inhibits metastasis independently of its effects on differentiation. In&#x000a0;vivo genetic reconstitution experiments show that miR-203 inhibits lung metastasis by suppressing the prometastatic activities of three factors involved in cytoskeletal dynamics (LASP1), extracellular matrix remodeling (SPARC), and cell metabolism (NUAK1). Expression of miR-203 and its downstream effectors correlates with HNSCC overall survival outcomes, indicating the therapeutic potential of targeting this signaling axis.</p></abstract><abstract abstract-type="graphical"><title>Graphical Abstract</title><fig id="undfig1" position="anchor"><graphic xlink:href="fx1"/></fig></abstract><abstract abstract-type="author-highlights"><title>Highlights</title><p><list list-type="simple"><list-item id="u0010"><label>&#x02022;</label><p>miR-203 regulates in&#x000a0;vivo lung metastasis without triggering differentiation</p></list-item><list-item id="u0015"><label>&#x02022;</label><p>Restoring miR-203 in already established metastases elicits regression</p></list-item><list-item id="u0020"><label>&#x02022;</label><p>LASP1, NUAK1, and SPARC are downstream prometastatic effectors of miR-203</p></list-item><list-item id="u0025"><label>&#x02022;</label><p>The miR-203-LASP1/SPARC/NUAK1 axis is prognostic of overall survival in HNSCC</p></list-item></list></p></abstract><abstract abstract-type="teaser"><p>Benaich et&#x000a0;al. have identified miR-203, a microRNA that triggers differentiation in multilayered epithelia, as an inhibitor of lung metastasis in head and neck squamous cell carcinoma (HNSCC) cells. They show that miR-203 inhibits metastasis independently of its effects on differentiation. Rather, miR-203 suppresses the prometastatic activities of three factors involved in cytoskeletal dynamics (LASP1), extracellular matrix remodeling (SPARC), and cell metabolism (NUAK1). Expression of miR-203 and its downstream effectors correlates with survival in HNSCC patients.</p></abstract></article-meta><notes><p id="misc0010">Published: October 2, 2014</p></notes></front><body><sec sec-type="intro" id="sec1"><title>Introduction</title><p>Adult stratified epithelia are maintained by a balance between stem cell self-renewal and differentiation (<xref rid="bib4 bib5" ref-type="bibr">Arwert et&#x000a0;al., 2012; Blanpain and Fuchs, 2006</xref>). As emerging neoplastic drivers, stem cells and the factors that control their biology are of therapeutic relevance in carcinomas (<xref rid="bib29" ref-type="bibr">Pardal et&#x000a0;al., 2003</xref>). For example, <italic>NOTCH1</italic> and <italic>TP63</italic> form a negative feedback loop in epidermal stem cells, with <italic>NOTCH1</italic> promoting differentiation and <italic>TP63</italic> inhibiting it (<xref rid="bib25" ref-type="bibr">Nguyen et&#x000a0;al., 2006</xref>). Inactivation of these genes is associated with skin tumors in mice (<xref rid="bib12 bib26" ref-type="bibr">Flores et&#x000a0;al., 2005; Nicolas et&#x000a0;al., 2003</xref>) and head and neck squamous cell carcinoma (HNSCC) in humans (<xref rid="bib1 bib38" ref-type="bibr">Agrawal et&#x000a0;al., 2011; Stransky et&#x000a0;al., 2011</xref>). Thus, disruption of the epithelial stem cell molecular circuitry can play a driving role in malignant transformation of the tissues they replenish.</p><p>HNSCC is the sixth most common cancer worldwide and has had a 5-year overall survival rate of only &#x0223c;50% for decades (<xref rid="bib19" ref-type="bibr">Leemans et&#x000a0;al., 2011</xref>). Two-thirds of patients present with advanced, locally invasive disease that recurs despite mainstay surgery or chemo- and/or radiotherapy, thus creating a pressing need for novel avenues of therapeutic intervention (<xref rid="bib3" ref-type="bibr">Argiris et&#x000a0;al., 2008</xref>).</p><p>Metastasis accounts for &#x0003e;90% of solid-cancer-related deaths (<xref rid="bib44" ref-type="bibr">Valastyan and Weinberg, 2011</xref>). Metastatic dissemination can occur early in the evolution of a tumor, followed by extended dormancy (<xref rid="bib14" ref-type="bibr">H&#x000fc;semann et&#x000a0;al., 2008</xref>). Indeed, up to 40% of carcinoma cases without clinical evidence of metastasis actually harbor disseminated tumor cells in the bone marrow (<xref rid="bib28" ref-type="bibr">Pantel and Brakenhoff, 2004</xref>). Thus, truly efficacious cancer therapeutics must target&#x000a0;already established metastases rather than just inhibit tumor growth or dissemination (<xref rid="bib44" ref-type="bibr">Valastyan and Weinberg, 2011</xref>).</p><p>miRNAs are small noncoding RNAs that posttranscriptionally repress target mRNAs important for tissue homeostasis and cancer (<xref rid="bib21 bib46" ref-type="bibr">Lujambio and Lowe, 2012; Valastyan et&#x000a0;al., 2009b</xref>). Although our understanding of metastasis-relevant miRNAs has advanced rapidly in well-studied malignancies such as breast cancer (<xref rid="bib45 bib47 bib48 bib50" ref-type="bibr">Valastyan et&#x000a0;al., 2009a, 2010, 2011; Yi et&#x000a0;al., 2008</xref>), we know little about whether and how miRNAs modulate metastasis in HNSCC. Therefore, we employed functional in&#x000a0;vivo approaches to identify miR-203 as a potent negative regulator of HNSCC metastasis by targeting a panel of prometastatic effector proteins (<xref rid="bib50" ref-type="bibr">Yi et&#x000a0;al., 2008</xref>).</p></sec><sec sec-type="results" id="sec2"><title>Results</title><sec id="sec2.1"><title>A Screen of miRNAs in HNSCC Identifies miR-203 as a Metastasis Suppressor</title><p>To uncover endogenous miRNAs that reduce the lung metastatic potential of HNSCC, we employed the screening approach shown in <xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>A. Using a panel of 17 primary, early-passage human HNSCC cell lines from surgically resected tumors, we assayed the expression of 15 miRNAs identified as coordinately deregulated in published expression profiles of HNSCC (see the&#x000a0;<xref rid="app3" ref-type="sec">Supplemental Experimental Procedures</xref>). We identified five&#x000a0;downregulated miRNAs (miR-26b, miR-125b, miR-203, miR-218, and miR-373) and one upregulated miRNA (miR-15a) when we compared miRNA expression in HNSCC cells versus primary human keratinocytes (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>A). miR-133a and miR-133b were not detected in any lines.</p><p>To assess the function of the deregulated miRNAs in HNSCC, we generated two YFP-luciferase-expressing cell lines&#x02014;SCC13 (established facial SCC; <xref rid="bib32" ref-type="bibr">Rheinwald and Beckett, 1981</xref>) and SJG15 (primary lingual SCC; <xref rid="bib13" ref-type="bibr">Goldie et&#x000a0;al., 2012</xref>)&#x02014;in which we knocked down miR-15a or stably overexpressed miR-26b, miR-125b, miR-203, miR-218, or miR-373 using lentiviral approaches (<xref rid="app3" ref-type="sec">Figure&#x000a0;S1</xref>A). No antiproliferative or cytotoxic effects were observed in&#x000a0;vitro in adherent cultures (<xref rid="app3" ref-type="sec">Figure&#x000a0;S1</xref>C).</p><p>We explored the function of these miRNAs in an in&#x000a0;vivo orthotopic tongue xenograft assay that recapitulates aspects of human HNSCC (<xref rid="bib13" ref-type="bibr">Goldie et&#x000a0;al., 2012</xref>). SCC13 cells were injected into the lingual mucosa of nonobese diabetic/severe combined immunodeficient interleukin-2 receptor-&#x003b3; chain null (NSG) mice (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>A), and noninvasive, luciferase-based bioluminescent imaging was used to monitor disease progression (<xref rid="bib16 bib41" ref-type="bibr">Kim et&#x000a0;al., 2010; Tiffen et&#x000a0;al., 2010</xref>). Xenografting 10<sup>5</sup> miRNA expressing SCC13 cells revealed that overexpression of miR-203 and knockdown of miR-15a modestly reduced tumor burden after 26&#x000a0;days compared with control. The other miRNAs did not affect tumor burden (<xref rid="fig1" ref-type="fig">Figures 1</xref>B and <xref rid="app3" ref-type="sec">S1</xref>D).</p><p>To measure metastatic dissemination from the primary tumors, we imaged the lungs of tumor-bearing mice ex&#x000a0;vivo at 26&#x000a0;days (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>C). Overexpression of miR-26b and miR-218 enhanced metastatic dissemination, whereas the other four miRNAs had no significant effect (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>D). Since the aim of the screen was to identify antimetastatic miRNAs, we did not analyze miR-26b and miR-218 further.</p><p>To examine metastatic colonization independently of primary tumor growth, we intravenously injected miRNA-expressing SCC13 and SJG15 cells into NSG mice (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>A). Overexpression of miR-203 or knockdown of miR-15a suppressed metastasis in both cell lines, as determined by endpoint lung metastatic burden, ex&#x000a0;vivo fluorescence microscopy, and histology (<xref rid="fig1" ref-type="fig">Figures 1</xref>E and <xref rid="app3" ref-type="sec">S1</xref>E&#x02013;S1H). miR-125b and miR-373 were excluded from further analysis because their effects were not consistent between SCC13 and SJG15 cells. Since miR-15a is a tumor suppressor (<xref rid="bib2" ref-type="bibr">Aqeilan et&#x000a0;al., 2010</xref>), we expressed miR-15a in otherwise nonmetastatic, miR-15a<sup>low</sup> SCC25 cells (established lingual SCC; <xref rid="bib32" ref-type="bibr">Rheinwald and Beckett, 1981</xref>; <xref rid="app3" ref-type="sec">Figure&#x000a0;S1</xref>B). Overexpression of miR-15a did not enhance lung metastatic colonization by SCC25 cells (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>F), so we did not analyze this miR further.</p><p>With miR-203 presenting the most compelling case as a metastasis-suppressor gene, we explored its clinical relevance in a cohort of 219 HNSCC patients from The Cancer Genome Atlas (TCGA) (data available through the TCGA Data Portal; <xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>G). The 5-year survival rate of miR-203-low patients was 36%, compared with 70% for miR-203-high patients, independently of primary tumor size (T1/T2 versus T3/T4). Patients with miR-203-low tumors also exhibited significantly more lymph node-positive disease and lymphovascular invasion&#x02014;two major prognostic factors for eventual distant metastasis. Hence, miR-203 is a prognostic indicator of overall survival and propensity for metastasis.</p><p>Using high-resolution copy-number data for 322 HNSCC patients from TCGA, we detected a copy-number alteration (CNA) harboring miR-203 that was focally deleted in 15% of cases (<xref rid="app3" ref-type="sec">Figure&#x000a0;S2</xref>B). This CNA included several genes that have been implicated in suppressing epithelial tumorigenesis and/or metastasis, such as DICER1 (<xref rid="bib22" ref-type="bibr">Martello et&#x000a0;al., 2010</xref>) and ELF5 (<xref rid="bib6" ref-type="bibr">Chakrabarti et&#x000a0;al., 2012</xref>). The miR-203 locus was also deleted in cutaneous melanoma (34% of cases), lung adenocarcinoma (29% of cases), and glioblastoma multiforme (28% of cases) (<xref rid="app3" ref-type="sec">Figure&#x000a0;S2</xref>C). Therefore, deregulation of miR-203 in HNSCC (and potentially other tumor types) is due, at least in part, to focal CNAs that alter&#x000a0;multiple tumor- and/or metastasis-suppressive pathways.</p></sec><sec id="sec2.2"><title>Effect of miR-203 Expression on Primary Tumor Growth</title><p>To examine miR-203 expression in&#x000a0;vivo, we performed in&#x000a0;situ hybridization in 28 cases of primary and/or metastatic skin SCCs with matched normal skin from the same patients, and three further cases of skin SCC (total of 11 patients; <xref rid="app3" ref-type="sec">Table S1</xref>). Whereas miR-203 was strongly expressed in the suprabasal, differentiated layers of normal epidermis, confirming previous reports (<xref rid="bib50" ref-type="bibr">Yi et&#x000a0;al., 2008</xref>), its expression was 35-fold lower in matched cutaneous SCCs (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>A).</p><p>We found that miR-203 significantly reduced both the average number and size of spheres formed by SCC13 in soft agar (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>B and data not shown), consistent with the observation that when 10<sup>5</sup> cells were injected into the tongue, miR-203 reduced tumor growth (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>B). To assess the impact on tumor growth in more detail, we xenografted 10<sup>4</sup> SCC13 cells expressing miR-203 or scrambled control hairpin (SCR) and monitored tumors for up to 50&#x000a0;days (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>C). We confirmed miR-203 expression by in&#x000a0;situ hybridization (<xref rid="app3" ref-type="sec">Figure&#x000a0;S3</xref>B). The reduction in tumor size upon expression of miR-203 was due to a lag in the initial rate of growth, and from week 2 onward the rate of tumor growth was comparable to that in control SCC13 cells (<xref rid="fig2" ref-type="fig">Figures 2</xref>C and <xref rid="app3" ref-type="sec">S3</xref>A).</p><p>To investigate whether miR-203 affected the proportion of cells that were capable of initiating primary tumors, we performed a limiting dilution analysis (LDA) (<xref rid="bib18" ref-type="bibr">Lapouge et&#x000a0;al., 2012</xref>) in which 10<sup>4</sup>, 10<sup>3</sup>, 100, or 10 SCC13 SCR or miR-203 cells were injected into the tongue (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>D). No difference in tumor incidence was observed between miR-203- and SCR-expressing cells (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>D). There was, however, a lag in tumor growth phase at all seeding densities (<xref rid="fig2" ref-type="fig">Figures 2</xref>C and <xref rid="app3" ref-type="sec">S1</xref>D; data not shown).</p><p>We conclude that miR-203 overexpression does not affect the number of tumor-initiating cells or the overall tumor growth rate, but causes a delay before tumor growth becomes established, which results in a reduction in tumor size. This may explain the lack of a correlation between T stage and miR-203 expression in HNSCC patients, since, at least in xenografts, the effect on tumor size is more marked at early time points (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>G).</p></sec><sec id="sec2.3"><title>miR-203 Expression Inhibits Lung Metastasis</title><p>We measured the circulating tumor DNA content by extracting whole peripheral blood 50&#x000a0;days after tongue xenografting (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>C) and determined the levels of human <italic>AluJ</italic> or <italic>hLine1</italic> repeat elements by quantitative PCR (qPCR) (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>E). There was no difference in circulating tumor DNA content between mice bearing miR-203 or control SCC13 primary tumors (<xref rid="fig2" ref-type="fig">Figures&#x000a0;2</xref>E and <xref rid="app3" ref-type="sec">S3</xref>C). However, ex&#x000a0;vivo bioluminescence and fluorescence imaging of lungs showed that miR-203-expressing SCC13 cells founded smaller metastases than control cells (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>F). Therefore, miR-203 does not alter the ability of cells from the primary tumor to enter the circulation, but does hamper their capacity to expand following engraftment in the lungs.</p><p>Consistent with these results, miR-203-expressing SCC13 and SJG15 cells exhibited a dose-dependent impairment in lung colonization following tail-vein injection (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>G). Expression of miR-203 significantly prolonged the time required for SCC13 and SJG15 cells to reach input levels of lung bioluminescence, suggesting that miR-203 extended the dormancy phase of engrafted cells (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>G), mirroring the phenotype observed in primary tumors (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>C). Expression of miR-203 significantly increased survival time (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>H) and reduced the endpoint lung metastatic burden (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>I). This was confirmed by ex&#x000a0;vivo fluorescence microscopy and anti-keratin-14 immunohistochemistry (IHC) of lungs (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>J and <xref rid="app3" ref-type="sec">S3</xref>E). Whereas control SCC13 and SJG15 cells colonized the majority of the lung area, cells expressing miR-203 only generated small metastatic lesions or remained as clusters of individual cells (<xref rid="app3" ref-type="sec">Figure&#x000a0;S3</xref>F). We confirmed that miR-203 expression was sustained in SCC13 lung metastases (<xref rid="app3" ref-type="sec">Figure&#x000a0;S3</xref>G). Taken together, these data suggest that miR-203 regulates the outgrowth of tumor cells once they have reached the lung.</p><p>We next asked whether endogenous miR-203 was necessary to prevent metastasis. For this purpose, we used SJG27 cells (primary lingual SCC), which express high levels of miR-203 and do not readily metastasize. Silencing miR-203 (miR-203 KD) in YFP-luciferase-labeled SJG27 cells did not impair proliferation in&#x000a0;vitro (<xref rid="app3" ref-type="sec">Figures S3</xref>H and S3I), but did enhance formation of clonogenic spheres in soft agar (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>A). When injected into the circulation of mice, miR-203 KD SJG27 cells were significantly more proficient at forming lung metastases over 65&#x000a0;days compared with control cells (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>B). Knockdown of miR-203 reduced the time to metastatic progression (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>C) and enhanced the total lung metastatic burden (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>D). Ex&#x000a0;vivo fluorescence microscopy and anti-keratin-5 IHC showed that miR-203 KD cells generated more numerous and larger nodules than control cells (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>E). Clusters of individual cells were visible in control, but not miR-203 KD, lungs, further suggesting a role for miR-203 in maintaining dormancy (<xref rid="app3" ref-type="sec">Figure&#x000a0;S3</xref>J).</p><p>We conclude, on the basis of miR-203 knockdown and overexpression, that miR-203 inhibits lung metastasis of HNSCC.</p></sec><sec id="sec2.4"><title>miR-203 Regulates Multiple Postextravasation Events and Inhibits Established Metastases</title><p>We next used a doxycycline (dox)-inducible system to temporally control miR-203 expression (<xref rid="fig4" ref-type="fig">Figures 4</xref>A, 4B, and <xref rid="app3" ref-type="sec">S4</xref>A). Dox-inducible miR-203 expression did not affect in&#x000a0;vitro proliferation of adherent cells (<xref rid="app3" ref-type="sec">Figure&#x000a0;S4</xref>B), but reduced the anchorage-independent growth of SCC13 cells in soft agar (<xref rid="app3" ref-type="sec">Figure&#x000a0;S4</xref>C), consistent with the effect of constitutive expression (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>B).</p><p>We activated miR-203 expression at defined time points following intravenous injection of SCC13 cells (<xref rid="fig4" ref-type="fig">Figure&#x000a0;4</xref>B). Expression of miR-203 was either never induced (mimicking cells lacking miR-203), induced before intravenous injection&#x000a0;(day 0, phenocopying constitutive miR-203 expression), or induced 10 (dormancy phase of engrafted cells), 29 (establishment of micrometastases), or 56&#x000a0;days (macrometastatic colonization) after injection.</p><p>Animals injected with scrambled control cells that were never induced or induced from day 0, 10, 29, or 56 all had similar disease burdens, arguing against any effects of the dox-rich diet (<xref rid="fig4" ref-type="fig">Figures 4</xref>C&#x02013;4E and data not shown). An examination of RFP and GFP signals from lung metastases in each cohort of animals, as well as in&#x000a0;situ hybridization for miR-203, confirmed dox-dependent, sustained expression of miR-203 in&#x000a0;vivo (<xref rid="app3" ref-type="sec">Figures S4</xref>D&#x02013;S4F and data not shown).</p><p>Activation of miR-203 for the duration of the experiment resulted in a 95% inhibition of endpoint lung metastatic burden (<xref rid="fig4" ref-type="fig">Figures 4</xref>C and 4D). Reexpression of miR-203 from 10 or 29&#x000a0;days was sufficient to block 80% of the endpoint lung metastatic burden (<xref rid="fig4" ref-type="fig">Figures 4</xref>C and 4D). Ex&#x000a0;vivo fluorescence microscopy of lungs confirmed that reintroduction of miR-203 substantially reduced the number and size of lung metastases (<xref rid="fig4" ref-type="fig">Figure&#x000a0;4</xref>E). Although it was not statistically significant, animals in which miR-203 was induced for only the final 2&#x000a0;weeks of the experiment had &#x0223c;40% lower lung metastasis (<xref rid="fig4" ref-type="fig">Figures 4</xref>C and 4D) accompanied by a moderate reduction in lesion size and number (<xref rid="fig4" ref-type="fig">Figure&#x000a0;4</xref>E).</p><p>We next investigated whether miR-203 affects cancer cell extravasation across the lung vasculature in&#x000a0;vivo (<xref rid="fig4" ref-type="fig">Figure&#x000a0;4</xref>F). Thirty hours after intravenous injection, multiphoton confocal imaging of individual GFP<sup>+</sup> tumor cells and tomato lectin-labeled blood vessels revealed that a similar proportion (&#x0223c;90%) of control and miR-203-expressing SCC13 cells had successfully extravasated (<xref rid="fig4" ref-type="fig">Figure&#x000a0;4</xref>G).</p><p>We conclude that miR-203 inhibits lung metastasis by inhibiting exit from dormancy, rather than by preventing migration from the primary tumor or entry into the lung.</p></sec><sec id="sec2.5"><title>miR-203 Induces Mutually Exclusive Transcriptomic Landscapes Characteristic of Keratinocyte Differentiation and Poorly Metastatic Cells</title><p>To probe the mechanisms by which miR-203 regulates metastasis, we performed genome-wide expression profiling and gene set enrichment analysis (GSEA) of miR-203-expressing SCC13 and SJG15 cells versus scrambled controls. Genome-wide expression changes elicited by miR-203 were negatively enriched for signatures of metastasis in primary human HNSCC arising in various anatomical locations within the aerodigestive tract (<xref rid="bib9 bib27 bib34" ref-type="bibr">Cromer et&#x000a0;al., 2004; O&#x02019;Donnell et&#x000a0;al., 2005; Rickman et&#x000a0;al., 2008</xref>; <xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>A). A similar negative enrichment between miR-203 and metastasis signatures was also found in melanoma, breast, prostate, and endometrial tumors, all of which have a tendency to metastasize (data not shown). Together, these results suggest that miR-203 enforces a transcriptional landscape in human HNSCC cells that is restrictive for metastasis.</p><p>GSEA also revealed that signatures of human keratinocyte differentiation were positively enriched in miR-203-expressing HNSCC cells (<xref rid="bib17 bib24 bib36" ref-type="bibr">Kretz et&#x000a0;al., 2012; Mulder et&#x000a0;al., 2012; Sen et&#x000a0;al., 2010</xref>; <xref rid="fig5" ref-type="fig">Figures 5</xref>A and 5B). However, there was no overlap between the core genes driving the metastasis and differentiation signatures (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>C). This suggests that miR-203 uses mutually exclusive genetic strategies to prime the transcriptional landscape of HNSCC cells toward a poorly metastatic cell state and a differentiated state. In support of this prediction, there was no difference between control and miR-203-expressing SCC13 tongue tumors and lung metastases in expression of markers of undifferentiated keratinocytes, including keratin-5, keratin-14, &#x003b1;6-integrin, and p63. There was no difference in E-cadherin expression, and all tumors were negative for the epithelial-mesenchymal transition (EMT) markers N-cadherin and vimentin, with the exception of a few cells at the invasive edge (<xref rid="app3" ref-type="sec">Figures S5</xref>A and S5B; cf. <xref rid="bib40" ref-type="bibr">Taube et&#x000a0;al., 2013</xref>). There was also no difference in expression of the keratinocyte differentiation markers involucrin, keratin 10, and loricrin (<xref rid="app3" ref-type="sec">Figures S5</xref>C and S5D), or in markers of proliferation (Ki67 and phospho-histone H3), apoptosis (cleaved-caspase 3 positive), or vascular density (<xref rid="app3" ref-type="sec">Figures S6</xref>A&#x02013;S6C).</p><p>Hence, although miR-203 primed the transcriptional landscape of HNSCC cells toward a differentiated state, primary tumors and lung metastases did not exhibit alterations in differentiation status in&#x000a0;vivo. These results suggest that the mechanism by which miR-203 controls metastasis is distinct from its prodifferentiation function in normal epidermis (<xref rid="bib50" ref-type="bibr">Yi et&#x000a0;al., 2008</xref>).</p></sec><sec id="sec2.6"><title>miR-203 Directly Targets a Cohort of Genes Upregulated in HNSCC</title><p>To identify prometastatic miR-203 target genes, we used an integrated genomics, bioinformatics, and experimental approach (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>D). We curated our microarray expression data for genes significantly downregulated by miR-203 and overlapped these hits (171 genes) with a list of 993 miR-203 predicted target genes from 11 publically available algorithms. To enrich for relevance in human HNSCC, we filtered the 13 hits through Oncomine (<xref rid="bib33" ref-type="bibr">Rhodes et&#x000a0;al., 2007</xref>) and the Human Protein Atlas (<xref rid="bib43" ref-type="bibr">Uhlen et&#x000a0;al., 2010</xref>), and discovered four genes (<italic>LASP1</italic>, <italic>NUAK1</italic>, <italic>SPARC</italic>, and <italic>THBS2</italic>) that were upregulated in HNSCC specimens relative to normal mucosa. Furthermore, we observed tumor-specific upregulation of <italic>LASP1</italic>, <italic>NUAK1</italic>, <italic>SPARC</italic>, and <italic>THBS2</italic> in an independent cohort of 24 oral SCC patients not contained in Oncomine (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>F; <xref rid="bib33" ref-type="bibr">Rhodes et&#x000a0;al., 2007</xref>). Genes associated with the actions of miR-203 in other cancers, such as BIRC5 (<xref rid="bib35" ref-type="bibr">Saini et&#x000a0;al., 2011</xref>), SNAI2 (<xref rid="bib11" ref-type="bibr">Ding et&#x000a0;al., 2013</xref>), P63 (<xref rid="bib50" ref-type="bibr">Yi et&#x000a0;al., 2008</xref>), and c-Jun (<xref rid="bib37" ref-type="bibr">Sonkoly et&#x000a0;al., 2012</xref>), were not enriched in our samples.</p><p>To validate the results of our analysis, we showed that overexpression of miR-203 led to downregulation of LASP1, NUAK1, SPARC, and THBS2 in SCC13 and SJG15 cells (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>E). Dox induction of miR-203 in SCC13 and SJG15 cells led to&#x000a0;downregulation of LASP1, NUAK1, and SPARC, but not THBS2 (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>G).</p><p>We focused on LASP1, NUAK1, and SPARC because of their involvement in metastasis-relevant processes such as cytoskeletal dynamics, energy metabolism, and extracellular matrix remodeling, respectively, and their previously described roles in cancer (<xref rid="bib20 bib23 bib42" ref-type="bibr">Liu et&#x000a0;al., 2012; Minn et&#x000a0;al., 2005; Traenka et&#x000a0;al., 2010</xref>). To determine whether or not <italic>LASP1</italic>, <italic>NUAK1</italic>, and <italic>SPARC</italic> are direct miR-203 targets, we cloned the 3&#x02032; UTRs into a luciferase reporter construct. The 3&#x02032; UTR of <italic>TP63</italic>, a known downstream target of miR-203 (<xref rid="bib50" ref-type="bibr">Yi et&#x000a0;al., 2008</xref>), served as a positive control. Transfection of exogenous miR-203 molecules (mimics) into 293T cells led to specific upregulation of miR-203 levels (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>H). miR-203 mimics repressed the <italic>LASP1</italic>, <italic>NUAK1</italic>, <italic>SPARC</italic>, and <italic>TP63</italic> 3&#x02032; UTR reporters, while mutation of the various miR-203 binding sites blocked miR-203-mediated regulation of each 3&#x02032; UTR (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>I). Western blotting showed a miR-203-dependent reduction in LASP1, NUAK1, and SPARC protein levels (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>J). Moreover, we found significant negative correlations between RNA sequencing (RNAseq) read counts of miR-203 and each of its three direct targets, but not <italic>TP63</italic>, across 225 HNSCC patients in TCGA (<xref rid="app3" ref-type="sec">Figure&#x000a0;S2</xref>A). We thus confirmed LASP1, NUAK1, and SPARC as direct target genes of miR-203 in human HNSCC.</p></sec><sec id="sec2.7"><title>LASP1, NUAK1, and SPARC Are Functionally Important Prometastatic Downstream Effectors of miR-203 that Are Prognostic of Overall Survival in HNSCC</title><p>To investigate the functional contribution(s) of LASP1, NUAK1, and SPARC to miR-203-induced inhibition of metastasis, we conducted genetic rescue experiments in&#x000a0;vivo (<xref rid="fig6" ref-type="fig">Figure&#x000a0;6</xref>A). We engineered control and miR-203 expressing SCC13 cells to stably express all 16 possible combinations of miRNA-insensitive cDNAs (lacking 3&#x02032; UTRs) encoding <italic>LASP1</italic>, <italic>NUAK1</italic>, and <italic>SPARC</italic>, and validated correct target gene reconstitution by western blotting (<xref rid="fig6" ref-type="fig">Figure&#x000a0;6</xref>B). The levels of exogenous protein expressed were sufficiently high that endogenous NUAK1 and SPARC (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>J) could not be seen on the blots (<xref rid="fig6" ref-type="fig">Figure&#x000a0;6</xref>B).</p><p>All 16 SCC13 populations were intravenously injected into mice and lung metastasis was monitored for up to 88&#x000a0;days (<xref rid="fig6" ref-type="fig">Figures 6</xref>C, <xref rid="app3" ref-type="sec">S6</xref>D, and S6E). Consistent with our earlier findings (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>), SCC13 cells expressing miR-203 together with three empty-vector controls (3xEV) did not colonize the lungs, whereas 3xEV SCC13 SCR cells generated numerous macrometastatic lesions (<xref rid="fig6" ref-type="fig">Figure&#x000a0;6</xref>C). Overexpression of SPARC or NUAK1 alone led to a small increase in metastasis of miR-203 cells, whereas overexpression of LASP1 alone caused a pronounced stimulation, which was comparable to overexpressing all three proteins (<xref rid="fig6" ref-type="fig">Figures 6</xref>C, <xref rid="app3" ref-type="sec">S6</xref>E, and S6E). Overexpression of LASP1 and/or SPARC, or combined expression of LASP1, SPARC, and NUAK1 did not enhance metastasis of SCR SCC13 cells (<xref rid="fig6" ref-type="fig">Figures 6</xref>C&#x02013;6F, <xref rid="app3" ref-type="sec">S6</xref>D, and <xref rid="app3" ref-type="sec">S6</xref>E). Unexpectedly, when NUAK1 was expressed alone or in combination with SPARC or LASP1, SCR SCC13 cells produced fewer metastases (<xref rid="fig6" ref-type="fig">Figures 6</xref>F and <xref rid="app3" ref-type="sec">S6</xref>E).</p><p>Individual or combined reintroduction of NUAK1, SPARC, and/or LASP1 was sufficient to bolster the lung metastatic colonization by SCC13 expressing miR-203 (<xref rid="fig6" ref-type="fig">Figure&#x000a0;6</xref>C&#x02013;6F). NUAK1, SPARC, and LASP1 promoted exit from dormancy (<xref rid="fig6" ref-type="fig">Figure&#x000a0;6</xref>D) and overt pulmonary colonization, increasing the lung metastatic burden by 7-fold, 10-fold, and 53-fold, respectively (<xref rid="fig6" ref-type="fig">Figures 6</xref>E and 6F). Thus, each miR-203 target promotes metastasis in the presence of miR-203, with the effect of LASP1 being most pronounced. In addition, knockdown of LASP1 reduced the clonogenic potential of SCC13 cells in&#x000a0;vitro (<xref rid="app3" ref-type="sec">Figures S6</xref>F and S6G), recreating the phenotype observed when miR-203 is expressed in the SCC13 cell line (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>B).</p><p>The clinical relevance of the miR-203 target genes was confirmed in patient data. High expression of <italic>LASP1</italic>, <italic>NUAK1</italic>, and <italic>SPARC</italic> correlated with poor prognosis in both the TCGA cohort and a separate publically available HNSCC cohort (<xref rid="fig6" ref-type="fig">Figures 6</xref>G and 6H; <xref rid="bib9" ref-type="bibr">Cromer et&#x000a0;al., 2004</xref>).</p><p>We conclude that miR-203 inhibits lung metastasis, not by triggering differentiation, but by directly targeting the prometastatic genes <italic>LASP1</italic>, <italic>SPARC</italic>, and <italic>NUAK1</italic>, which are prognostic factors in human HNSCC.</p></sec></sec><sec sec-type="discussion" id="sec3"><title>Discussion</title><p>Our studies uncover miR-203 as a potent suppressor of key postextravasation events during lung metastasis. Reintroducing miR-203 into already established pulmonary nodules elicits their regression, suggesting the potential for therapeutic modalities aimed at activating miR-203 in cancer cells to treat metastatic HNSCC.</p><p>Recent evidence suggests that cancer cells hijack normal stem cell self-renewal signaling pathways to generate and propagate tumors in&#x000a0;vivo (<xref rid="bib31" ref-type="bibr">Reis et&#x000a0;al., 2011</xref><italic>)</italic>. If so, coaxing cancer cells to differentiate may inhibit tumor growth and metastasis. Although miR-203 promotes differentiation of normal epidermal stem cells (<xref rid="bib15 bib50" ref-type="bibr">Jackson et&#x000a0;al., 2013; Yi et&#x000a0;al., 2008</xref>), our study shows that it does not promote carcinoma differentiation in&#x000a0;vivo. Instead, miR-203 controls HNSCC metastasis by targeting a network of prometastatic proteins, including LASP1, SPARC, and NUAK1. Thus, we propose that miR-203 undergoes a context-dependent functional switch from regulating normal differentiation to acting as a differentiation-independent roadblock to metastasis.</p><p>It is known that the genetic and epigenetic alterations sustained by host cells during malignant transformation alter the repertoire of mRNA species available for targeting by miRNAs (<xref rid="bib21" ref-type="bibr">Lujambio and Lowe, 2012</xref>). Thus, miRNAs can perform cellular-context-dependent functions driven by different cohorts of downstream effectors. For example, miR-126 inhibits breast cancer metastasis either by modulating the primary tumor microenvironment (<xref rid="bib51" ref-type="bibr">Zhang et&#x000a0;al., 2013</xref>) or by inhibiting lung metastatic colonization (<xref rid="bib30" ref-type="bibr">Png et&#x000a0;al., 2012</xref>) in mouse or human breast cancer models, respectively. As such, the rewiring of miR-203 function from regulating differentiation to inhibiting metastasis is likely to be explained by changes in target gene selection from differentiation-relevant proteins, such as TP63, to metastasis-promoting factors, such as LASP1, SPARC, and NUAK1.</p><p>Our mechanistic studies identify LASP1, SPARC, and NUAK1 as important direct downstream effectors for miR-203-mediated inhibition of HNSCC metastasis. Prior studies have shown that these proteins promote cancer cell migration and invasion in&#x000a0;vitro, promote tumor progression and/or metastasis in&#x000a0;vivo, and correlate with poor overall survival in diverse carcinomas (<xref rid="bib7 bib8 bib10 bib20 bib23 bib39 bib42 bib49" ref-type="bibr">Chang et&#x000a0;al., 2012; Chin et&#x000a0;al., 2005; Davis et&#x000a0;al., 2008; Liu et&#x000a0;al., 2012; Minn et&#x000a0;al., 2005; Suzuki et&#x000a0;al., 2004; Traenka et&#x000a0;al., 2010; Viticchi&#x000e8; et&#x000a0;al., 2011</xref>). We speculate that LASP1, NUAK1, and SPARC promote postextravasation survival and/or engraftment, shorten dormancy, and bolster overt pulmonary colonization by HNSCC cells.</p><p>Our data indicate that miR-203 is an upstream governor of several distinct cellular pathways that converge to enforce a poorly metastatic cell state, and highlight the importance of cellular context in determining the effects of a specific miRNA on metastasis. Indeed, miR-203 regulates tumor progression in breast and prostate cancer, but the targets of its action are very distinct among tissue types. In advanced metastatic prostate cancer, miR-203 targets BIRC5 (<xref rid="bib35" ref-type="bibr">Saini et&#x000a0;al., 2011</xref>), whereas in breast cancer metastasis it targets SNAI2 (<xref rid="bib11" ref-type="bibr">Ding et&#x000a0;al., 2013</xref>). This suggests that miR-203 not only functionally switches between tissue homeostasis and cancer progression, as shown here, but also switches targets depending on the cancer type.</p><p>In conclusion, our studies highlight miR-203 and its effectors as promising routes for therapeutic intervention in metastatic HNSCC. Unlike most anticancer agents and antimetastatic strategies currently in clinical trials (<xref rid="bib44" ref-type="bibr">Valastyan and Weinberg, 2011</xref>), miR-203 can antagonize metastasis even after cancer cells have seeded the lung and formed clinically advanced nodules. In light of the development of targeted strategies to deliver nucleic acids into tumor cells (<xref rid="bib10" ref-type="bibr">Davis et&#x000a0;al., 2008</xref>), we envision the potential value of using miR-203 mimetics to alleviate otherwise therapeutically intractable metastatic HNSCC.</p></sec><sec sec-type="methods" id="sec4"><title>Experimental Procedures</title><sec id="sec4.1"><title>Cell Lines</title><p>SCC13, SCC25, SJG cell lines, and normal keratinocytes were cultured in FAD medium under standard conditions. Work with human material was either carried out in compliance with the UK Human Tissue Act (2004) and approved by the National Research Ethics Service (08/H0306/30) or according to the recommendations of the local ethics committee and the German Medical Council for diagnostic tissue used in research.</p></sec><sec id="sec4.2"><title>Animal Studies</title><p>Tongue xenografting and experimental lung metastasis experiments were performed as previously described (<xref rid="bib13" ref-type="bibr">Goldie et&#x000a0;al., 2012</xref>). Animal studies were subject to Cancer Research UK and King&#x02019;s College London ethical review and performed in accordance with an approved UK Government Home Office license. A dox-rich diet (Harlan) was used to induce miR-203 expression in&#x000a0;vivo. Bioluminescent imaging was conducted using a Xenogen IVIS 200 system (Perkin Elmer).</p></sec><sec id="sec4.3"><title>qRT-PCR, Microarrays, and GEO Data Sets</title><p>RNA was isolated using a miRNeasy Mini Kit (QIAGEN), and qRT-PCR was performed using TaqMan probes (Life Technologies) and SYBR Green primers. Genome-wide expression analysis was carried out on Illumina Human HT12 version 4 arrays. Microarray data sets <ext-link ext-link-type="uri" xlink:href="ncbi-geo:GSE31056" id="intref0010">GSE31056</ext-link> and <ext-link ext-link-type="uri" xlink:href="ncbi-geo:GSE2379" id="intref0015">GSE2379</ext-link> were downloaded from NCBI GEO. TCGA data were downloaded from <ext-link ext-link-type="uri" xlink:href="https://tcga-data.nci.nih.gov/tcga/" id="intref0020">https://tcga-data.nci.nih.gov/tcga/</ext-link> and <ext-link ext-link-type="uri" xlink:href="http://www.broadinstitute.org/tcga/home" id="intref0025">http://www.broadinstitute.org/tcga/home</ext-link>.</p></sec><sec id="sec4.4"><title>Statistical Analysis</title><p>An unpaired two-tailed Student&#x02019;s t test (in&#x000a0;vitro experiments) or a nonparametric Mann-Whitney test (in&#x000a0;vivo mouse experiments) was used for comparisons, with p&#x000a0;&#x0003c; 0.05 considered significant. A log rank (Mantel-Cox) test was&#x000a0;used to compare survival curves and compute hazard ratios, and Fisher&#x02019;s&#x000a0;exact test used to compare human cohorts on the basis of clinical characteristics.</p></sec></sec><sec sec-type="acknowledgement" id="sec5"><title>Author Contributions</title><p>N.B. and F.M.W. conceived the project. N.B., S.W., and F.M.W. wrote the manuscript. N.B., S.W., and A.M. performed experiments. S.J.G. and S.R.Q. provided reagents.</p></sec></body><back><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name><surname>Agrawal</surname><given-names>N.</given-names></name><name><surname>Frederick</surname><given-names>M.J.</given-names></name><name><surname>Pickering</surname><given-names>C.R.</given-names></name><name><surname>Bettegowda</surname><given-names>C.</given-names></name><name><surname>Chang</surname><given-names>K.</given-names></name><name><surname>Li</surname><given-names>R.J.</given-names></name><name><surname>Fakhry</surname><given-names>C.</given-names></name><name><surname>Xie</surname><given-names>T.X.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name></person-group><article-title>Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1</article-title><source>Science</source><volume>333</volume><year>2011</year><fpage>1154</fpage><lpage>1157</lpage><pub-id pub-id-type="pmid">21798897</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name><surname>Aqeilan</surname><given-names>R.I.</given-names></name><name><surname>Calin</surname><given-names>G.A.</given-names></name><name><surname>Croce</surname><given-names>C.M.</given-names></name></person-group><article-title>miR-15a and miR-16-1 in cancer: discovery, function and future perspectives</article-title><source>Cell Death Differ.</source><volume>17</volume><year>2010</year><fpage>215</fpage><lpage>220</lpage><pub-id pub-id-type="pmid">19498445</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name><surname>Argiris</surname><given-names>A.</given-names></name><name><surname>Karamouzis</surname><given-names>M.V.</given-names></name><name><surname>Raben</surname><given-names>D.</given-names></name><name><surname>Ferris</surname><given-names>R.L.</given-names></name></person-group><article-title>Head and neck cancer</article-title><source>Lancet</source><volume>371</volume><year>2008</year><fpage>1695</fpage><lpage>1709</lpage><pub-id pub-id-type="pmid">18486742</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name><surname>Arwert</surname><given-names>E.N.</given-names></name><name><surname>Hoste</surname><given-names>E.</given-names></name><name><surname>Watt</surname><given-names>F.M.</given-names></name></person-group><article-title>Epithelial stem cells, wound healing and cancer</article-title><source>Nat. Rev. Cancer</source><volume>12</volume><year>2012</year><fpage>170</fpage><lpage>180</lpage><pub-id pub-id-type="pmid">22362215</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name><surname>Blanpain</surname><given-names>C.</given-names></name><name><surname>Fuchs</surname><given-names>E.</given-names></name></person-group><article-title>Epidermal stem cells of the skin</article-title><source>Annu. Rev. Cell Dev. Biol.</source><volume>22</volume><year>2006</year><fpage>339</fpage><lpage>373</lpage><pub-id pub-id-type="pmid">16824012</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name><surname>Chakrabarti</surname><given-names>R.</given-names></name><name><surname>Hwang</surname><given-names>J.</given-names></name><name><surname>Andres Blanco</surname><given-names>M.</given-names></name><name><surname>Wei</surname><given-names>Y.</given-names></name><name><surname>Luka&#x0010d;i&#x00161;in</surname><given-names>M.</given-names></name><name><surname>Romano</surname><given-names>R.A.</given-names></name><name><surname>Smalley</surname><given-names>K.</given-names></name><name><surname>Liu</surname><given-names>S.</given-names></name><name><surname>Yang</surname><given-names>Q.</given-names></name><name><surname>Ibrahim</surname><given-names>T.</given-names></name></person-group><article-title>Elf5 inhibits the epithelial-mesenchymal transition in mammary gland development and breast cancer metastasis by transcriptionally repressing Snail2</article-title><source>Nat. Cell Biol.</source><volume>14</volume><year>2012</year><fpage>1212</fpage><lpage>1222</lpage><pub-id pub-id-type="pmid">23086238</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>X.Z.</given-names></name><name><surname>Yu</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>H.Y.</given-names></name><name><surname>Dong</surname><given-names>R.H.</given-names></name><name><surname>Cao</surname><given-names>X.C.</given-names></name></person-group><article-title>ARK5 is associated with the invasive and metastatic potential of human breast cancer cells</article-title><source>J.&#x000a0;Cancer Res. Clin. Oncol.</source><volume>138</volume><year>2012</year><fpage>247</fpage><lpage>254</lpage><pub-id pub-id-type="pmid">22105900</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name><surname>Chin</surname><given-names>D.</given-names></name><name><surname>Boyle</surname><given-names>G.M.</given-names></name><name><surname>Williams</surname><given-names>R.M.</given-names></name><name><surname>Ferguson</surname><given-names>K.</given-names></name><name><surname>Pandeya</surname><given-names>N.</given-names></name><name><surname>Pedley</surname><given-names>J.</given-names></name><name><surname>Campbell</surname><given-names>C.M.</given-names></name><name><surname>Theile</surname><given-names>D.R.</given-names></name><name><surname>Parsons</surname><given-names>P.G.</given-names></name><name><surname>Coman</surname><given-names>W.B.</given-names></name></person-group><article-title>Novel markers for poor prognosis in head and neck cancer</article-title><source>Int. J. Cancer</source><volume>113</volume><year>2005</year><fpage>789</fpage><lpage>797</lpage><pub-id pub-id-type="pmid">15499618</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name><surname>Cromer</surname><given-names>A.</given-names></name><name><surname>Carles</surname><given-names>A.</given-names></name><name><surname>Millon</surname><given-names>R.</given-names></name><name><surname>Ganguli</surname><given-names>G.</given-names></name><name><surname>Chalmel</surname><given-names>F.</given-names></name><name><surname>Lemaire</surname><given-names>F.</given-names></name><name><surname>Young</surname><given-names>J.</given-names></name><name><surname>Demb&#x000e9;l&#x000e9;</surname><given-names>D.</given-names></name><name><surname>Thibault</surname><given-names>C.</given-names></name><name><surname>Muller</surname><given-names>D.</given-names></name></person-group><article-title>Identification of genes associated with tumorigenesis and metastatic potential of hypopharyngeal cancer by microarray analysis</article-title><source>Oncogene</source><volume>23</volume><year>2004</year><fpage>2484</fpage><lpage>2498</lpage><pub-id pub-id-type="pmid">14676830</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name><surname>Davis</surname><given-names>M.E.</given-names></name><name><surname>Chen</surname><given-names>Z.G.</given-names></name><name><surname>Shin</surname><given-names>D.M.</given-names></name></person-group><article-title>Nanoparticle therapeutics: an emerging treatment modality for cancer</article-title><source>Nat. Rev. Drug Discov.</source><volume>7</volume><year>2008</year><fpage>771</fpage><lpage>782</lpage><pub-id pub-id-type="pmid">18758474</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>X.</given-names></name><name><surname>Park</surname><given-names>S.I.</given-names></name><name><surname>McCauley</surname><given-names>L.K.</given-names></name><name><surname>Wang</surname><given-names>C.-Y.</given-names></name></person-group><article-title>Signaling between transforming growth factor &#x003b2; (TGF-&#x003b2;) and transcription factor SNAI2 represses expression of microRNA miR-203 to promote epithelial-mesenchymal transition and tumor metastasis</article-title><source>J.&#x000a0;Biol. Chem.</source><volume>288</volume><year>2013</year><fpage>10241</fpage><lpage>10253</lpage><pub-id pub-id-type="pmid">23447531</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name><surname>Flores</surname><given-names>E.R.</given-names></name><name><surname>Sengupta</surname><given-names>S.</given-names></name><name><surname>Miller</surname><given-names>J.B.</given-names></name><name><surname>Newman</surname><given-names>J.J.</given-names></name><name><surname>Bronson</surname><given-names>R.</given-names></name><name><surname>Crowley</surname><given-names>D.</given-names></name><name><surname>Yang</surname><given-names>A.</given-names></name><name><surname>McKeon</surname><given-names>F.</given-names></name><name><surname>Jacks</surname><given-names>T.</given-names></name></person-group><article-title>Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family</article-title><source>Cancer Cell</source><volume>7</volume><year>2005</year><fpage>363</fpage><lpage>373</lpage><pub-id pub-id-type="pmid">15837625</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name><surname>Goldie</surname><given-names>S.J.</given-names></name><name><surname>Mulder</surname><given-names>K.W.</given-names></name><name><surname>Tan</surname><given-names>D.W.M.</given-names></name><name><surname>Lyons</surname><given-names>S.K.</given-names></name><name><surname>Sims</surname><given-names>A.H.</given-names></name><name><surname>Watt</surname><given-names>F.M.</given-names></name></person-group><article-title>FRMD4A upregulation in human squamous cell carcinoma promotes tumor growth and metastasis and is associated with poor prognosis</article-title><source>Cancer Res.</source><volume>72</volume><year>2012</year><fpage>3424</fpage><lpage>3436</lpage><pub-id pub-id-type="pmid">22564525</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name><surname>H&#x000fc;semann</surname><given-names>Y.</given-names></name><name><surname>Geigl</surname><given-names>J.B.</given-names></name><name><surname>Schubert</surname><given-names>F.</given-names></name><name><surname>Musiani</surname><given-names>P.</given-names></name><name><surname>Meyer</surname><given-names>M.</given-names></name><name><surname>Burghart</surname><given-names>E.</given-names></name><name><surname>Forni</surname><given-names>G.</given-names></name><name><surname>Eils</surname><given-names>R.</given-names></name><name><surname>Fehm</surname><given-names>T.</given-names></name><name><surname>Riethm&#x000fc;ller</surname><given-names>G.</given-names></name><name><surname>Klein</surname><given-names>C.A.</given-names></name></person-group><article-title>Systemic spread is an early step in breast cancer</article-title><source>Cancer Cell</source><volume>13</volume><year>2008</year><fpage>58</fpage><lpage>68</lpage><pub-id pub-id-type="pmid">18167340</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name><surname>Jackson</surname><given-names>S.J.</given-names></name><name><surname>Zhang</surname><given-names>Z.</given-names></name><name><surname>Feng</surname><given-names>D.</given-names></name><name><surname>Flagg</surname><given-names>M.</given-names></name><name><surname>O&#x02019;Loughlin</surname><given-names>E.</given-names></name><name><surname>Wang</surname><given-names>D.</given-names></name><name><surname>Stokes</surname><given-names>N.</given-names></name><name><surname>Fuchs</surname><given-names>E.</given-names></name><name><surname>Yi</surname><given-names>R.</given-names></name></person-group><article-title>Rapid and widespread suppression of self-renewal by microRNA-203 during epidermal differentiation</article-title><source>Development</source><volume>140</volume><year>2013</year><fpage>1882</fpage><lpage>1891</lpage><pub-id pub-id-type="pmid">23571213</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>J.B.</given-names></name><name><surname>Urban</surname><given-names>K.</given-names></name><name><surname>Cochran</surname><given-names>E.</given-names></name><name><surname>Lee</surname><given-names>S.</given-names></name><name><surname>Ang</surname><given-names>A.</given-names></name><name><surname>Rice</surname><given-names>B.</given-names></name><name><surname>Bata</surname><given-names>A.</given-names></name><name><surname>Campbell</surname><given-names>K.</given-names></name><name><surname>Coffee</surname><given-names>R.</given-names></name><name><surname>Gorodinsky</surname><given-names>A.</given-names></name></person-group><article-title>Non-invasive detection of a small number of bioluminescent cancer cells in&#x000a0;vivo</article-title><source>PLoS ONE</source><volume>5</volume><year>2010</year><fpage>e9364</fpage><pub-id pub-id-type="pmid">20186331</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name><surname>Kretz</surname><given-names>M.</given-names></name><name><surname>Webster</surname><given-names>D.E.</given-names></name><name><surname>Flockhart</surname><given-names>R.J.</given-names></name><name><surname>Lee</surname><given-names>C.S.</given-names></name><name><surname>Zehnder</surname><given-names>A.</given-names></name><name><surname>Lopez-Pajares</surname><given-names>V.</given-names></name><name><surname>Qu</surname><given-names>K.</given-names></name><name><surname>Zheng</surname><given-names>G.X.</given-names></name><name><surname>Chow</surname><given-names>J.</given-names></name><name><surname>Kim</surname><given-names>G.E.</given-names></name></person-group><article-title>Suppression of progenitor differentiation requires the long noncoding RNA ANCR</article-title><source>Genes Dev.</source><volume>26</volume><year>2012</year><fpage>338</fpage><lpage>343</lpage><pub-id pub-id-type="pmid">22302877</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name><surname>Lapouge</surname><given-names>G.</given-names></name><name><surname>Beck</surname><given-names>B.</given-names></name><name><surname>Nassar</surname><given-names>D.</given-names></name><name><surname>Dubois</surname><given-names>C.</given-names></name><name><surname>Dekoninck</surname><given-names>S.</given-names></name><name><surname>Blanpain</surname><given-names>C.</given-names></name></person-group><article-title>Skin squamous cell carcinoma propagating cells increase with tumour progression and invasiveness</article-title><source>EMBO J.</source><volume>31</volume><year>2012</year><fpage>4563</fpage><lpage>4575</lpage><pub-id pub-id-type="pmid">23188079</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name><surname>Leemans</surname><given-names>C.R.</given-names></name><name><surname>Braakhuis</surname><given-names>B.J.M.</given-names></name><name><surname>Brakenhoff</surname><given-names>R.H.</given-names></name></person-group><article-title>The molecular biology of head and neck cancer</article-title><source>Nat. Rev. Cancer</source><volume>11</volume><year>2011</year><fpage>9</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">21160525</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>L.</given-names></name><name><surname>Ulbrich</surname><given-names>J.</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>J.</given-names></name><name><surname>W&#x000fc;stefeld</surname><given-names>T.</given-names></name><name><surname>Aeberhard</surname><given-names>L.</given-names></name><name><surname>Kress</surname><given-names>T.R.</given-names></name><name><surname>Muthalagu</surname><given-names>N.</given-names></name><name><surname>Rycak</surname><given-names>L.</given-names></name><name><surname>Rudalska</surname><given-names>R.</given-names></name><name><surname>Moll</surname><given-names>R.</given-names></name></person-group><article-title>Deregulated MYC expression induces dependence upon AMPK-related kinase 5</article-title><source>Nature</source><volume>483</volume><year>2012</year><fpage>608</fpage><lpage>612</lpage><pub-id pub-id-type="pmid">22460906</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name><surname>Lujambio</surname><given-names>A.</given-names></name><name><surname>Lowe</surname><given-names>S.W.</given-names></name></person-group><article-title>The microcosmos of cancer</article-title><source>Nature</source><volume>482</volume><year>2012</year><fpage>347</fpage><lpage>355</lpage><pub-id pub-id-type="pmid">22337054</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name><surname>Martello</surname><given-names>G.</given-names></name><name><surname>Rosato</surname><given-names>A.</given-names></name><name><surname>Ferrari</surname><given-names>F.</given-names></name><name><surname>Manfrin</surname><given-names>A.</given-names></name><name><surname>Cordenonsi</surname><given-names>M.</given-names></name><name><surname>Dupont</surname><given-names>S.</given-names></name><name><surname>Enzo</surname><given-names>E.</given-names></name><name><surname>Guzzardo</surname><given-names>V.</given-names></name><name><surname>Rondina</surname><given-names>M.</given-names></name><name><surname>Spruce</surname><given-names>T.</given-names></name></person-group><article-title>A MicroRNA targeting dicer for metastasis control</article-title><source>Cell</source><volume>141</volume><year>2010</year><fpage>1195</fpage><lpage>1207</lpage><pub-id pub-id-type="pmid">20603000</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name><surname>Minn</surname><given-names>A.J.</given-names></name><name><surname>Gupta</surname><given-names>G.P.</given-names></name><name><surname>Siegel</surname><given-names>P.M.</given-names></name><name><surname>Bos</surname><given-names>P.D.</given-names></name><name><surname>Shu</surname><given-names>W.</given-names></name><name><surname>Giri</surname><given-names>D.D.</given-names></name><name><surname>Viale</surname><given-names>A.</given-names></name><name><surname>Olshen</surname><given-names>A.B.</given-names></name><name><surname>Gerald</surname><given-names>W.L.</given-names></name><name><surname>Massagu&#x000e9;</surname><given-names>J.</given-names></name></person-group><article-title>Genes that mediate breast cancer metastasis to lung</article-title><source>Nature</source><volume>436</volume><year>2005</year><fpage>518</fpage><lpage>524</lpage><pub-id pub-id-type="pmid">16049480</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name><surname>Mulder</surname><given-names>K.W.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Escriu</surname><given-names>C.</given-names></name><name><surname>Ito</surname><given-names>Y.</given-names></name><name><surname>Schwarz</surname><given-names>R.F.</given-names></name><name><surname>Gillis</surname><given-names>J.</given-names></name><name><surname>Sirokm&#x000e1;ny</surname><given-names>G.</given-names></name><name><surname>Donati</surname><given-names>G.</given-names></name><name><surname>Uribe-Lewis</surname><given-names>S.</given-names></name><name><surname>Pavlidis</surname><given-names>P.</given-names></name></person-group><article-title>Diverse epigenetic strategies interact to control epidermal differentiation</article-title><source>Nat. Cell Biol.</source><volume>14</volume><year>2012</year><fpage>753</fpage><lpage>763</lpage><pub-id pub-id-type="pmid">22729083</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>B.C.</given-names></name><name><surname>Lefort</surname><given-names>K.</given-names></name><name><surname>Mandinova</surname><given-names>A.</given-names></name><name><surname>Antonini</surname><given-names>D.</given-names></name><name><surname>Devgan</surname><given-names>V.</given-names></name><name><surname>Della Gatta</surname><given-names>G.</given-names></name><name><surname>Koster</surname><given-names>M.I.</given-names></name><name><surname>Zhang</surname><given-names>Z.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Tommasi di Vignano</surname><given-names>A.</given-names></name></person-group><article-title>Cross-regulation between Notch and p63 in keratinocyte commitment to differentiation</article-title><source>Genes Dev.</source><volume>20</volume><year>2006</year><fpage>1028</fpage><lpage>1042</lpage><pub-id pub-id-type="pmid">16618808</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name><surname>Nicolas</surname><given-names>M.</given-names></name><name><surname>Wolfer</surname><given-names>A.</given-names></name><name><surname>Raj</surname><given-names>K.</given-names></name><name><surname>Kummer</surname><given-names>J.A.</given-names></name><name><surname>Mill</surname><given-names>P.</given-names></name><name><surname>van Noort</surname><given-names>M.</given-names></name><name><surname>Hui</surname><given-names>C.C.</given-names></name><name><surname>Clevers</surname><given-names>H.</given-names></name><name><surname>Dotto</surname><given-names>G.P.</given-names></name><name><surname>Radtke</surname><given-names>F.</given-names></name></person-group><article-title>Notch1 functions as a tumor suppressor in mouse skin</article-title><source>Nat. Genet.</source><volume>33</volume><year>2003</year><fpage>416</fpage><lpage>421</lpage><pub-id pub-id-type="pmid">12590261</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><name><surname>O&#x02019;Donnell</surname><given-names>R.K.</given-names></name><name><surname>Kupferman</surname><given-names>M.</given-names></name><name><surname>Wei</surname><given-names>S.J.</given-names></name><name><surname>Singhal</surname><given-names>S.</given-names></name><name><surname>Weber</surname><given-names>R.</given-names></name><name><surname>O&#x02019;Malley</surname><given-names>B.</given-names></name><name><surname>Cheng</surname><given-names>Y.</given-names></name><name><surname>Putt</surname><given-names>M.</given-names></name><name><surname>Feldman</surname><given-names>M.</given-names></name><name><surname>Ziober</surname><given-names>B.</given-names></name><name><surname>Muschel</surname><given-names>R.J.</given-names></name></person-group><article-title>Gene expression signature predicts lymphatic metastasis in squamous cell carcinoma of the oral cavity</article-title><source>Oncogene</source><volume>24</volume><year>2005</year><fpage>1244</fpage><lpage>1251</lpage><pub-id pub-id-type="pmid">15558013</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal" id="sref28"><person-group person-group-type="author"><name><surname>Pantel</surname><given-names>K.</given-names></name><name><surname>Brakenhoff</surname><given-names>R.H.</given-names></name></person-group><article-title>Dissecting the metastatic cascade</article-title><source>Nat. Rev. Cancer</source><volume>4</volume><year>2004</year><fpage>448</fpage><lpage>456</lpage><pub-id pub-id-type="pmid">15170447</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal" id="sref29"><person-group person-group-type="author"><name><surname>Pardal</surname><given-names>R.</given-names></name><name><surname>Clarke</surname><given-names>M.F.</given-names></name><name><surname>Morrison</surname><given-names>S.J.</given-names></name></person-group><article-title>Applying the principles of stem-cell biology to cancer</article-title><source>Nat. Rev. Cancer</source><volume>3</volume><year>2003</year><fpage>895</fpage><lpage>902</lpage><pub-id pub-id-type="pmid">14737120</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name><surname>Png</surname><given-names>K.J.</given-names></name><name><surname>Halberg</surname><given-names>N.</given-names></name><name><surname>Yoshida</surname><given-names>M.</given-names></name><name><surname>Tavazoie</surname><given-names>S.F.</given-names></name></person-group><article-title>A microRNA regulon that mediates endothelial recruitment and metastasis by cancer cells</article-title><source>Nature</source><volume>481</volume><year>2012</year><fpage>190</fpage><lpage>194</lpage><pub-id pub-id-type="pmid">22170610</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal" id="sref31"><person-group person-group-type="author"><name><surname>Reis</surname><given-names>P.P.</given-names></name><name><surname>Waldron</surname><given-names>L.</given-names></name><name><surname>Perez-Ordonez</surname><given-names>B.</given-names></name><name><surname>Pintilie</surname><given-names>M.</given-names></name><name><surname>Galloni</surname><given-names>N.N.</given-names></name><name><surname>Xuan</surname><given-names>Y.</given-names></name><name><surname>Cervigne</surname><given-names>N.K.</given-names></name><name><surname>Warner</surname><given-names>G.C.</given-names></name><name><surname>Makitie</surname><given-names>A.A.</given-names></name><name><surname>Simpson</surname><given-names>C.</given-names></name></person-group><article-title>A gene signature in histologically normal surgical margins is predictive of oral carcinoma recurrence</article-title><source>BMC Cancer</source><volume>11</volume><year>2011</year><fpage>437</fpage><pub-id pub-id-type="pmid">21989116</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal" id="sref32"><person-group person-group-type="author"><name><surname>Rheinwald</surname><given-names>J.G.</given-names></name><name><surname>Beckett</surname><given-names>M.A.</given-names></name></person-group><article-title>Tumorigenic keratinocyte lines requiring anchorage and fibroblast support cultured from human squamous cell carcinomas</article-title><source>Cancer Res.</source><volume>41</volume><year>1981</year><fpage>1657</fpage><lpage>1663</lpage><pub-id pub-id-type="pmid">7214336</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal" id="sref33"><person-group person-group-type="author"><name><surname>Rhodes</surname><given-names>D.R.</given-names></name><name><surname>Kalyana-Sundaram</surname><given-names>S.</given-names></name><name><surname>Mahavisno</surname><given-names>V.</given-names></name><name><surname>Varambally</surname><given-names>R.</given-names></name><name><surname>Yu</surname><given-names>J.</given-names></name><name><surname>Briggs</surname><given-names>B.B.</given-names></name><name><surname>Barrette</surname><given-names>T.R.</given-names></name><name><surname>Anstet</surname><given-names>M.J.</given-names></name><name><surname>Kincead-Beal</surname><given-names>C.</given-names></name><name><surname>Kulkarni</surname><given-names>P.</given-names></name></person-group><article-title>Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles</article-title><source>Neoplasia</source><volume>9</volume><year>2007</year><fpage>166</fpage><lpage>180</lpage><pub-id pub-id-type="pmid">17356713</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal" id="sref34"><person-group person-group-type="author"><name><surname>Rickman</surname><given-names>D.S.</given-names></name><name><surname>Millon</surname><given-names>R.</given-names></name><name><surname>De Reynies</surname><given-names>A.</given-names></name><name><surname>Thomas</surname><given-names>E.</given-names></name><name><surname>Wasylyk</surname><given-names>C.</given-names></name><name><surname>Muller</surname><given-names>D.</given-names></name><name><surname>Abecassis</surname><given-names>J.</given-names></name><name><surname>Wasylyk</surname><given-names>B.</given-names></name></person-group><article-title>Prediction of future metastasis and molecular characterization of head and neck squamous-cell carcinoma based on transcriptome and genome analysis by microarrays</article-title><source>Oncogene</source><volume>27</volume><year>2008</year><fpage>6607</fpage><lpage>6622</lpage><pub-id pub-id-type="pmid">18679425</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal" id="sref35"><person-group person-group-type="author"><name><surname>Saini</surname><given-names>S.</given-names></name><name><surname>Majid</surname><given-names>S.</given-names></name><name><surname>Yamamura</surname><given-names>S.</given-names></name><name><surname>Tabatabai</surname><given-names>L.</given-names></name><name><surname>Suh</surname><given-names>S.O.</given-names></name><name><surname>Shahryari</surname><given-names>V.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Deng</surname><given-names>G.</given-names></name><name><surname>Tanaka</surname><given-names>Y.</given-names></name><name><surname>Dahiya</surname><given-names>R.</given-names></name></person-group><article-title>Regulatory role of mir-203 in prostate cancer progression and metastasis</article-title><source>Clin. Cancer Res.</source><volume>17</volume><year>2011</year><fpage>5287</fpage><lpage>5298</lpage><pub-id pub-id-type="pmid">21159887</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal" id="sref36"><person-group person-group-type="author"><name><surname>Sen</surname><given-names>G.L.</given-names></name><name><surname>Reuter</surname><given-names>J.A.</given-names></name><name><surname>Webster</surname><given-names>D.E.</given-names></name><name><surname>Zhu</surname><given-names>L.</given-names></name><name><surname>Khavari</surname><given-names>P.A.</given-names></name></person-group><article-title>DNMT1 maintains progenitor function in self-renewing somatic tissue</article-title><source>Nature</source><volume>463</volume><year>2010</year><fpage>563</fpage><lpage>567</lpage><pub-id pub-id-type="pmid">20081831</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal" id="sref37"><person-group person-group-type="author"><name><surname>Sonkoly</surname><given-names>E.</given-names></name><name><surname>Lov&#x000e9;n</surname><given-names>J.</given-names></name><name><surname>Xu</surname><given-names>N.</given-names></name><name><surname>Meisgen</surname><given-names>F.</given-names></name><name><surname>Wei</surname><given-names>T.</given-names></name><name><surname>Brodin</surname><given-names>P.</given-names></name><name><surname>Jaks</surname><given-names>V.</given-names></name><name><surname>Kasper</surname><given-names>M.</given-names></name><name><surname>Shimokawa</surname><given-names>T.</given-names></name><name><surname>Harada</surname><given-names>M.</given-names></name></person-group><article-title>MicroRNA-203 functions as a tumor suppressor in basal cell carcinoma</article-title><source>Oncogenesis</source><volume>1</volume><year>2012</year><fpage>e3</fpage><pub-id pub-id-type="pmid">23552555</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal" id="sref38"><person-group person-group-type="author"><name><surname>Stransky</surname><given-names>N.</given-names></name><name><surname>Egloff</surname><given-names>A.M.</given-names></name><name><surname>Tward</surname><given-names>A.D.</given-names></name><name><surname>Kostic</surname><given-names>A.D.</given-names></name><name><surname>Cibulskis</surname><given-names>K.</given-names></name><name><surname>Sivachenko</surname><given-names>A.</given-names></name><name><surname>Kryukov</surname><given-names>G.V.</given-names></name><name><surname>Lawrence</surname><given-names>M.S.</given-names></name><name><surname>Sougnez</surname><given-names>C.</given-names></name><name><surname>McKenna</surname><given-names>A.</given-names></name></person-group><article-title>The mutational landscape of head and neck squamous cell carcinoma</article-title><source>Science</source><volume>333</volume><year>2011</year><fpage>1157</fpage><lpage>1160</lpage><pub-id pub-id-type="pmid">21798893</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal" id="sref39"><person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>A.</given-names></name><name><surname>Lu</surname><given-names>J.</given-names></name><name><surname>Kusakai</surname><given-names>G.</given-names></name><name><surname>Kishimoto</surname><given-names>A.</given-names></name><name><surname>Ogura</surname><given-names>T.</given-names></name><name><surname>Esumi</surname><given-names>H.</given-names></name></person-group><article-title>ARK5 is a tumor invasion-associated factor downstream of Akt signaling</article-title><source>Mol. Cell. Biol.</source><volume>24</volume><year>2004</year><fpage>3526</fpage><lpage>3535</lpage><pub-id pub-id-type="pmid">15060171</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal" id="sref40"><person-group person-group-type="author"><name><surname>Taube</surname><given-names>J.H.</given-names></name><name><surname>Malouf</surname><given-names>G.G.</given-names></name><name><surname>Lu</surname><given-names>E.</given-names></name><name><surname>Sphyris</surname><given-names>N.</given-names></name><name><surname>Vijay</surname><given-names>V.</given-names></name><name><surname>Ramachandran</surname><given-names>P.P.</given-names></name><name><surname>Ueno</surname><given-names>K.R.</given-names></name><name><surname>Gaur</surname><given-names>S.</given-names></name><name><surname>Nicoloso</surname><given-names>M.S.</given-names></name><name><surname>Rossi</surname><given-names>S.</given-names></name></person-group><article-title>Epigenetic silencing of microRNA-203 is required for EMT and cancer stem cell properties</article-title><source>Sci Rep</source><volume>3</volume><year>2013</year><fpage>2687</fpage><pub-id pub-id-type="pmid">24045437</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal" id="sref41"><person-group person-group-type="author"><name><surname>Tiffen</surname><given-names>J.C.</given-names></name><name><surname>Bailey</surname><given-names>C.G.</given-names></name><name><surname>Ng</surname><given-names>C.</given-names></name><name><surname>Rasko</surname><given-names>J.E.J.</given-names></name><name><surname>Holst</surname><given-names>J.</given-names></name></person-group><article-title>Luciferase expression and bioluminescence does not affect tumor cell growth in&#x000a0;vitro or in&#x000a0;vivo</article-title><source>Mol. Cancer</source><volume>9</volume><year>2010</year><fpage>299</fpage><pub-id pub-id-type="pmid">21092230</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal" id="sref42"><person-group person-group-type="author"><name><surname>Traenka</surname><given-names>C.</given-names></name><name><surname>Remke</surname><given-names>M.</given-names></name><name><surname>Korshunov</surname><given-names>A.</given-names></name><name><surname>Bender</surname><given-names>S.</given-names></name><name><surname>Hielscher</surname><given-names>T.</given-names></name><name><surname>Northcott</surname><given-names>P.A.</given-names></name><name><surname>Witt</surname><given-names>H.</given-names></name><name><surname>Ryzhova</surname><given-names>M.</given-names></name><name><surname>Felsberg</surname><given-names>J.</given-names></name><name><surname>Benner</surname><given-names>A.</given-names></name></person-group><article-title>Role of LIM and SH3 protein 1 (LASP1) in the metastatic dissemination of medulloblastoma</article-title><source>Cancer Res.</source><volume>70</volume><year>2010</year><fpage>8003</fpage><lpage>8014</lpage><pub-id pub-id-type="pmid">20924110</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal" id="sref43"><person-group person-group-type="author"><name><surname>Uhlen</surname><given-names>M.</given-names></name><name><surname>Oksvold</surname><given-names>P.</given-names></name><name><surname>Fagerberg</surname><given-names>L.</given-names></name><name><surname>Lundberg</surname><given-names>E.</given-names></name><name><surname>Jonasson</surname><given-names>K.</given-names></name><name><surname>Forsberg</surname><given-names>M.</given-names></name><name><surname>Zwahlen</surname><given-names>M.</given-names></name><name><surname>Kampf</surname><given-names>C.</given-names></name><name><surname>Wester</surname><given-names>K.</given-names></name><name><surname>Hober</surname><given-names>S.</given-names></name></person-group><article-title>Towards a knowledge-based Human Protein Atlas</article-title><source>Nat. Biotechnol.</source><volume>28</volume><year>2010</year><fpage>1248</fpage><lpage>1250</lpage><pub-id pub-id-type="pmid">21139605</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal" id="sref44"><person-group person-group-type="author"><name><surname>Valastyan</surname><given-names>S.</given-names></name><name><surname>Weinberg</surname><given-names>R.A.</given-names></name></person-group><article-title>Tumor metastasis: molecular insights and evolving paradigms</article-title><source>Cell</source><volume>147</volume><year>2011</year><fpage>275</fpage><lpage>292</lpage><pub-id pub-id-type="pmid">22000009</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal" id="sref45"><person-group person-group-type="author"><name><surname>Valastyan</surname><given-names>S.</given-names></name><name><surname>Benaich</surname><given-names>N.</given-names></name><name><surname>Chang</surname><given-names>A.</given-names></name><name><surname>Reinhardt</surname><given-names>F.</given-names></name><name><surname>Weinberg</surname><given-names>R.A.</given-names></name></person-group><article-title>Concomitant suppression of three target genes can explain the impact of a microRNA on metastasis</article-title><source>Genes Dev.</source><volume>23</volume><year>2009</year><fpage>2592</fpage><lpage>2597</lpage><pub-id pub-id-type="pmid">19875476</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal" id="sref46"><person-group person-group-type="author"><name><surname>Valastyan</surname><given-names>S.</given-names></name><name><surname>Reinhardt</surname><given-names>F.</given-names></name><name><surname>Benaich</surname><given-names>N.</given-names></name><name><surname>Calogrias</surname><given-names>D.</given-names></name><name><surname>Sz&#x000e1;sz</surname><given-names>A.M.</given-names></name><name><surname>Wang</surname><given-names>Z.C.</given-names></name><name><surname>Brock</surname><given-names>J.E.</given-names></name><name><surname>Richardson</surname><given-names>A.L.</given-names></name><name><surname>Weinberg</surname><given-names>R.A.</given-names></name></person-group><article-title>A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis</article-title><source>Cell</source><volume>137</volume><year>2009</year><fpage>1032</fpage><lpage>1046</lpage><pub-id pub-id-type="pmid">19524507</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal" id="sref47"><person-group person-group-type="author"><name><surname>Valastyan</surname><given-names>S.</given-names></name><name><surname>Chang</surname><given-names>A.</given-names></name><name><surname>Benaich</surname><given-names>N.</given-names></name><name><surname>Reinhardt</surname><given-names>F.</given-names></name><name><surname>Weinberg</surname><given-names>R.A.</given-names></name></person-group><article-title>Concurrent suppression of integrin alpha5, radixin, and RhoA phenocopies the effects of miR-31 on metastasis</article-title><source>Cancer Res.</source><volume>70</volume><year>2010</year><fpage>5147</fpage><lpage>5154</lpage><pub-id pub-id-type="pmid">20530680</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal" id="sref48"><person-group person-group-type="author"><name><surname>Valastyan</surname><given-names>S.</given-names></name><name><surname>Chang</surname><given-names>A.</given-names></name><name><surname>Benaich</surname><given-names>N.</given-names></name><name><surname>Reinhardt</surname><given-names>F.</given-names></name><name><surname>Weinberg</surname><given-names>R.A.</given-names></name></person-group><article-title>Activation of miR-31 function in already-established metastases elicits metastatic regression</article-title><source>Genes Dev.</source><volume>25</volume><year>2011</year><fpage>646</fpage><lpage>659</lpage><pub-id pub-id-type="pmid">21406558</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal" id="sref49"><person-group person-group-type="author"><name><surname>Viticchi&#x000e8;</surname><given-names>G.</given-names></name><name><surname>Lena</surname><given-names>A.M.</given-names></name><name><surname>Latina</surname><given-names>A.</given-names></name><name><surname>Formosa</surname><given-names>A.</given-names></name><name><surname>Gregersen</surname><given-names>L.H.</given-names></name><name><surname>Lund</surname><given-names>A.H.</given-names></name><name><surname>Bernardini</surname><given-names>S.</given-names></name><name><surname>Mauriello</surname><given-names>A.</given-names></name><name><surname>Miano</surname><given-names>R.</given-names></name><name><surname>Spagnoli</surname><given-names>L.G.</given-names></name></person-group><article-title>MiR-203 controls proliferation, migration and invasive potential of prostate cancer cell lines</article-title><source>Cell Cycle</source><volume>10</volume><year>2011</year><fpage>1121</fpage><lpage>1131</lpage><pub-id pub-id-type="pmid">21368580</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal" id="sref50"><person-group person-group-type="author"><name><surname>Yi</surname><given-names>R.</given-names></name><name><surname>Poy</surname><given-names>M.N.</given-names></name><name><surname>Stoffel</surname><given-names>M.</given-names></name><name><surname>Fuchs</surname><given-names>E.</given-names></name></person-group><article-title>A skin microRNA promotes differentiation by repressing &#x02018;stemness&#x02019;</article-title><source>Nature</source><volume>452</volume><year>2008</year><fpage>225</fpage><lpage>229</lpage><pub-id pub-id-type="pmid">18311128</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal" id="sref51"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Yang</surname><given-names>P.</given-names></name><name><surname>Sun</surname><given-names>T.</given-names></name><name><surname>Li</surname><given-names>D.</given-names></name><name><surname>Xu</surname><given-names>X.</given-names></name><name><surname>Rui</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>C.</given-names></name><name><surname>Chong</surname><given-names>M.</given-names></name><name><surname>Ibrahim</surname><given-names>T.</given-names></name><name><surname>Mercatali</surname><given-names>L.</given-names></name></person-group><article-title>miR-126 and miR-126<sup>&#x02217;</sup> repress recruitment of mesenchymal stem cells and inflammatory monocytes to inhibit breast cancer metastasis</article-title><source>Nat. Cell Biol.</source><volume>15</volume><year>2013</year><fpage>284</fpage><lpage>294</lpage><pub-id pub-id-type="pmid">23396050</pub-id></element-citation></ref></ref-list><sec id="app1"><title>Accession Numbers</title><p>The NCBI Gene Expression Omnibus accession number for the gene expression data reported in this paper is <ext-link ext-link-type="uri" xlink:href="ncbi-geo:GSE47028" id="intref0030">GSE47028</ext-link>.</p></sec><sec id="app3" sec-type="supplementary-material"><title>Supplemental Information</title><p><supplementary-material content-type="local-data" id="mmc1"><caption><title>Document S1. Supplemental Experimental Procedures, Figures S1&#x02013;S6, and Table S1</title></caption><media xlink:href="mmc1.pdf"/></supplementary-material><supplementary-material content-type="local-data" id="mmc2"><caption><title>Document S2. Article plus Supplemental Information</title></caption><media xlink:href="mmc2.pdf"/></supplementary-material></p></sec><ack id="ack0010"><title>Acknowledgments</title><p>We thank Scott Valastyan, Alasdair Russell, Hironobu Fujiwara, Scott Lyons, Klaas Mulder, Carles Escriu, Andrew Sims, and the F.M.W. laboratory for helpful discussions and materials. We are grateful for experimental support from CRUK-CRI core facilities (Histopathology, Biological Resources, Genomics and Bioinformatics, Light Microscopy, Flow Cytometry, and the Equipment Park). N.B. was funded by a Gates Cambridge Scholarship and a Williams College Herchel Smith Fellowship. This research was funded by grants to F.M.W. from the EU Seventh Framework Programme (OptiStem), Medical Research Council (G1100073), Wellcome Trust (096540/Z/11/Z), and Cancer Research UK.</p></ack><fn-group><fn id="d32e271"><p>This is an open access article under the CC BY license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0/" id="ccintref0005">http://creativecommons.org/licenses/by/3.0/</ext-link>).</p></fn><fn id="app2" fn-type="supplementary-material"><p>Supplemental Information includes Supplemental Experimental Procedures, six figures, and one table and can be found with this article online at <ext-link ext-link-type="doi" xlink:href="10.1016/j.celrep.2014.08.062" id="intref0035">http://dx.doi.org/10.1016/j.celrep.2014.08.062</ext-link>.</p></fn></fn-group></back><floats-group><fig id="fig1"><label>Figure&#x000a0;1</label><caption><p>Candidate-Gene-Based Functional In&#x000a0;Vivo miRNA Screen</p><p>(A) Schematic of the pipeline for an in&#x000a0;vivo functional screen to identify miRNAs that regulate HNSCC lung metastasis. Heatmap of log<sub>2</sub> normalized qRT-PCR expression data for 13 miRNAs in 17 human HNSCC lines normalized to normal human oral keratinocytes. Data were clustered using cosine statistics.</p><p>(B) Fold primary tumor growth generated by 10<sup>5</sup> SCC13 cells individually expressing the indicated miRNA vectors after 26&#x000a0;days. Whiskers indicate min/max and the horizontal bar is the median, with n&#x000a0;= 4&#x02013;5 per group.</p><p>(C) Representative ex&#x000a0;vivo bioluminescent images of whole lungs at necropsy (day 26). Scale bar represents 3&#x000a0;mm.</p><p>(D) Total ex&#x000a0;vivo lung photon flux at endpoint (day 26). The horizontal line indicates mean, with n&#x000a0;= 5 per group.</p><p>(E) Lung metastatic burden resulting from tail-vein injection of SCC13 or SJG15 cells in which the levels of six miRNAs were individually modulated. Data are means &#x000b1; SEM, n&#x000a0;= 5 per group.</p><p>(F) Time course of experimental lung metastasis by SCC25 cells overexpressing miR-15a or control vector for 119&#x000a0;days. Log<sub>10</sub> y axis, data are means &#x000b1; SEM, n&#x000a0;= 5 per group.</p><p>(G) Kaplan-Meier plots for overall survival of 219 HNSCC patients from the TCGA cohort partitioned into miR-203-high (red, n&#x000a0;= 28) and miR-203-low (blue, n&#x000a0;=&#x000a0;191) cohorts based on miRNAseq read counts. The miR-203-high and -low patient cohorts were analyzed for the proportion of cases with lymph node disease (positive or negative), lymphovascular invasion (positive or negative), and primary tumor T-stage, which is a measure of tumour state and size.</p><p><sup>&#x02217;</sup>p&#x000a0;&#x0003c; 0.05; <sup>&#x02217;&#x02217;</sup>p&#x000a0;&#x0003c; 0.01; <sup>&#x02217;&#x02217;&#x02217;</sup>p&#x000a0;&#x0003c; 0.001 (nonparametric Mann-Whitney test). For Kaplan-Meier plots, p values were calculated using a log rank Mantel-Cox test. For patient cohort comparisons, p values were calculated using Fisher&#x02019;s exact test. See also <xref rid="app3" ref-type="sec">Figure&#x000a0;S1</xref>.</p></caption><graphic xlink:href="gr1"/></fig><fig id="fig2"><label>Figure&#x000a0;2</label><caption><p>miR-203 Inhibits Experimental Lung Metastasis</p><p>(A) Representative in&#x000a0;situ hybridization (red signal) for miR-203 and scrambled control probe in normal human skin (n&#x000a0;= 28) and malignant SCC (n&#x000a0;= 31) counterstained with DAPI nuclear label. Scale bar represents 50&#x000a0;&#x003bc;m. Adjacent panel: quantification of miR-203 signal intensity in normal skin versus SCC. Log<sub>10</sub> y axis.</p><p>(B) Anchorage-independent soft-agar assay. GFP<sup>+</sup> spheres were quantified after 3&#x000a0;weeks. Data are means &#x000b1; SEM.</p><p>(C) Fold primary tumor growth: 10<sup>4</sup> control and miR-203 expressing SCC13 cells were injected into the tongue and tumor growth was monitored by bioluminescent imaging. Raw photon flux was normalized to input levels and presented as mean &#x000b1; SEM; n&#x000a0;= 10 per group.</p><p>(D) Limited dilution analysis: 10<sup>4</sup>, 10<sup>3</sup>, 100, and 10 control and miR-203-expressing SCC13 cells were injected into the tongue. Tumor incidence (5-fold increase over baseline) was determined by bioluminescent imaging and tumors were monitored for up to 70&#x000a0;days (n&#x000a0;= 9).</p><p>(E) In&#x000a0;vivo tumor cell intravasation was inferred by using qRT-PCR for human-specific AluJ repeat elements present in circulating tumor cells within 200&#x000a0;&#x003bc;l whole blood. n&#x000a0;= 10 (SCR), n&#x000a0;= 9 (miR-203).</p><p>(F) Whole-mount lung fluorescence images from representative animals in (D). Scale bar represents 2&#x000a0;mm; left panels at 2&#x000d7; and right panels at 8&#x000d7; magnification. Quantification of lung metastasis by bioluminescence; data are means &#x000b1; SEM; n&#x000a0;= 7 (SCR), n&#x000a0;= 6 (miR-203).</p><p>(G) Lung metastatic colonization time course for SCC13 cells expressing high (n&#x000a0;= 10) or low miR-203 (n&#x000a0;= 5) and relevant controls, and SJG15 cells expressing miR-203 or scrambled control hairpin (n&#x000a0;= 5 each). Log<sub>10</sub> y axis. Data are means &#x000b1; SEM.</p><p>(H) Kaplan-Meier analysis for time to progression of lung metastasis. SCC13 SCR (n&#x000a0;= 15) and miR-203 groups (high and low; n&#x000a0;= 15) were pooled.</p><p>(I) Endpoint lung metastatic burden of animals from (F) injected with miR-203 expressing SCC13 cells (day 78) and SJG15 cells (day 91) normalized to control animals. Data are means &#x000b1; SEM.</p><p>(J) Representative whole-mount GFP fluorescence microscopy images of metastatic lung fields generated by miR-203 and control SCC13 and SJG15 cells. Scale bar represents 2&#x000a0;mm.</p><p><sup>&#x02217;</sup>p&#x000a0;&#x0003c; 0.05; <sup>&#x02217;&#x02217;</sup>p&#x000a0;&#x0003c; 0.01; <sup>&#x02217;&#x02217;&#x02217;</sup>p&#x000a0;&#x0003c; 0.001 calculated using the nonparametric Mann-Whitney test. The p values for the Kaplan-Meier plots were calculated using the log rank Mantel-Cox test. The p values for the soft-agar assay were calculated using the two-tailed Student&#x02019;s t test. See also <xref rid="app3" ref-type="sec">Figures S2</xref> and <xref rid="app3" ref-type="sec">S3</xref>.</p></caption><graphic xlink:href="gr2"/></fig><fig id="fig3"><label>Figure&#x000a0;3</label><caption><p>Silencing Endogenous miR-203 Enhances Lung Metastasis</p><p>(A) In&#x000a0;vitro soft-agar assay quantified at the first and second passages. Data are means &#x000b1; SEM, with representative wells shown; <sup>&#x02217;&#x02217;&#x02217;</sup>p&#x000a0;&#x0003c; 0.001 calculated using two-tailed Student&#x02019;s t test.</p><p>(B) Time course of experimental lung metastasis of miR-203 knockdown (KD) and control SJG27 cells over 65&#x000a0;days. Log<sub>10</sub> y axis; data are mean &#x000b1; SEM; n&#x000a0;= 5 per group.</p><p>(C) Kaplan-Meier plots for time to progression of lung metastasis of SJG27 SCR and miR-203-KD groups; p values were calculated using the log rank Mantel-Cox test.</p><p>(D) Lung metastasis by control and miR-203-KD SJG27 cells at day 65. Data are mean &#x000b1; SEM; n&#x000a0;= 5 per group; <sup>&#x02217;&#x02217;</sup>p&#x000a0;&#x0003c; 0.01 calculated using the nonparametric Mann-Whitney test.</p><p>(E) Representative whole-mount GFP fluorescence microscopy images and matched keratin-5 IHC of metastatic lungs. Scale bar represents 2&#x000a0;mm.</p><p>See also <xref rid="app3" ref-type="sec">Figure&#x000a0;S3</xref>.</p></caption><graphic xlink:href="gr3"/></fig><fig id="fig4"><label>Figure&#x000a0;4</label><caption><p>Inducible Restoration of miR-203</p><p>(A) Schematic representation of the dox-inducible miR-203 vector.</p><p>(B) Dox-mediated approach for reexpressing miR-203 following intravenous inoculation of SCC13 cells. Images represent single cells, micrometastases, and macrometastases (left to right) in the lung following tail-vein injection. Scale bar represents 500&#x000a0;&#x003bc;m.</p><p>(C) Time course of experimental lung metastases formed by inducible control (SCR) and miR-203-expressing SCC13 in animals on normal or dox-rich diets. Day indicates when the diet was switched to dox-rich. Log<sub>10</sub> y axis; data are means &#x000b1; SEM; n&#x000a0;= 4&#x02013;5 per group.</p><p>(D) Lung metastasis at endpoint (day 70) of noninduced or induced control and miR-203 SCC13 groups. Data are means &#x000b1; SEM; n&#x000a0;= 4&#x02013;5 per group; <sup>&#x02217;&#x02217;</sup>p&#x000a0;&#x0003c; 0.01 calculated using nonparametric Mann-Whitney test relative to noninduced miR-203 animals. Differences between SCR groups and noninduced miR-203 are nonsignificant.</p><p>(E) Representative whole-mount ex&#x000a0;vivo GFP fluorescence microscopy images of metastatic lungs at day 70. Scale bar represents 3&#x000a0;mm.</p><p>(F) Experimental strategy to quantify cancer cell extravasation across the lung vasculature in&#x000a0;vivo. Examples of GFP<sup>+</sup> SCC13 cells that have successfully extravasated (out) or are trapped within the lumen of pulmonary blood vessels labeled in red (in) and outlined with a dashed white line are shown. Scale bar represents 10&#x000a0;&#x003bc;m.</p><p>(G) Proportion of cells in or out of lung vasculature at 30&#x000a0;hr after intravenous injection. Data are mean % &#x000b1; SEM, with n&#x000a0;= 3 per group. A total of 127&#x02013;136 cells were counted per mouse.</p><p>See also <xref rid="app3" ref-type="sec">Figure&#x000a0;S4</xref>.</p></caption><graphic xlink:href="gr4"/></fig><fig id="fig5"><label>Figure&#x000a0;5</label><caption><p>LASP1, SPARC, and NUAK1 Are Direct Target Genes of miR-203</p><p>(A) GSEA plots showing negative enrichment of three signatures of genes upregulated in metastatic HNSCC (top row), and positive enrichment with three signatures of genes upregulated during primary human keratinocyte differentiation in&#x000a0;vitro (bottom row), in miR-203-expressing SJG15 cells compared with control. NES, normalized enrichment score; FDR, false-discovery rate q value.</p><p>(B) GSEA as in (A) using the ranked gene list (top upregulated to most downregulated) of genes in BMP2/7-treated keratinocytes compared with control.</p><p>(C) Leading-edge analysis of genes driving enrichment of metastasis and differentiation signatures in miR-203-expressing SJG15. Signatures on the vertical are abbreviated to first letters only on the horizontal axis. The overlap score (0&#x02013;1) indicates the degree to which leading-edge genes in each signature are shared with other signatures.</p><p>(D) Experimental and bioinformatics strategy to identify clinically relevant miR-203 target genes. Microarray expression profiling of stable miR-203 and control expressing SCC13 and SJG15 cells was followed by enrichment for downregulated direct targets using publically available miRNA target prediction algorithms, and subsequently analysis of microarray and protein expression data sets in Oncomine and the Human Protein Atlas to obtain four candidate target genes for validation.</p><p>(E) Heatmap depicting log<sub>2</sub> transformed expression levels of four candidate miR-203 target genes in the microarray experiments, validated by qRT-PCR in control and miR-203-expressing SCC13 and SJG15 cells.</p><p>(F) Analysis of GSE31056 for LASP1, NUAK1, SPARC, and THBS2 expression (counts) in normal tissue (24 samples), oral SCC margins (49 samples), and oral SCCs (23 samples); p values were calculated between normal and tumors using the nonparametric Mann-Whitney test.</p><p>(G) qRT-PCR for LASP1, NUAK1, SPARC, and THBS2 mRNA expression in SCC13 and SJG15 cells expressing inducible miR-203 or control vector. Cells were either not induced or induced for 3 consecutive days in&#x000a0;vitro. Expression normalized to GAPDH. Data are means &#x000b1; SEM.</p><p>(H) qRT-PCR expression of miR-15a and mi-20 in 293T cells transfected with 20&#x000a0;nM negative control miRNA (Ctrl miR) or miR-203 for luciferase reporter assays. Expression was normalized to Ctrl miR. Data are means &#x000b1; SEM.</p><p>(I) Luciferase reporter assays measuring the ability of transfected miR-203 to repress wild-type (left) and mutant (right) 3&#x02032; UTR sequences of LASP1, NUAK1, SPARC, and TP63 (positive control). Measurements are the ratios of firefly/renilla luminescence readings relative to control miRNA transfectants. Data are means&#x000a0;&#x000b1; SEM.</p><p>(J) Li-Cor western blots of whole-cell lysates (NUAK1, LASP1, and GAPDH) and conditioned medium (SPARC) from control (SCR) and miR-203-expressing SCC13 cell cultures.</p><p><sup>&#x02217;</sup>p&#x000a0;&#x0003c; 0.05, <sup>&#x02217;&#x02217;</sup>p&#x000a0;&#x0003c; 0.01, <sup>&#x02217;&#x02217;&#x02217;</sup>p&#x000a0;&#x0003c; 0.001 calculated using unpaired Student&#x02019;s t test. See also <xref rid="app3" ref-type="sec">Figures S5</xref> and <xref rid="app3" ref-type="sec">S6</xref>.</p></caption><graphic xlink:href="gr5"/></fig><fig id="fig6"><label>Figure&#x000a0;6</label><caption><p>LASP1, SPARC, and NUAK1 Can Overcome miR-203 Metastasis Suppression</p><p>(A) Schematic model for miR-203-driven suppression of lung metastatic fitness in SCC, and hypothesis for combinatorial genetic rescue by overexpression of miR-203-insensitive LASP1, NUAK1, and SPARC in miR-203-expressing SCC13 cells.</p><p>(B) Li-Cor western blots of 16 different whole-cell lysates from control (SCR) and miR-203-expressing SCC13 cells also overexpressing single, double, or triple combinations of LASP1, NUAK1, and SPARC cDNAs. GAPDH was used as a loading control.</p><p>(C) Time course of experimental lung metastasis generated by control (SCR) SCC13 cells expressing 3xEV and miR-203 SCC13 cells expressing 3xEV, NUAK1, SPARC, or LASP1, or NUAK1, SPARC, and LASP1 together (N+S+L) over 88&#x000a0;days (n&#x000a0;= 5 per group). Log<sub>10</sub> y axis; data are means &#x000b1; SEM with n&#x000a0;= 4&#x02013;5 per group. Data were selected from the full set of combinations presented in <xref rid="app3" ref-type="sec">Figure&#x000a0;S6</xref>D.</p><p>(D) Kaplan-Meier plots for time to progression of lung metastasis of control and miR-203 SCC13 cells expressing 3xEV, LASP1 alone, or all three target gene cDNAs; p values were calculated using the log rank Mantel-Cox test; n&#x000a0;= 4&#x02013;5 per group.</p><p>(E) Lung metastasis formed by 3xEV, NUAK1, SPARC, or LASP1, or NUAK1, SPARC, and LASP1 together (N+S+L) of miR203 SCC13 cell lines and 3xEV in the SCR SCC13 cell line, analyzed at day 88. Whiskers indicate min/max and the horizontal bar is median, with n&#x000a0;= 4&#x02013;5 per group. Log<sub>10</sub> y axis. <sup>&#x02217;</sup>p&#x000a0;&#x0003c; 0.05 and <sup>&#x02217;&#x02217;</sup>p&#x000a0;&#x0003c; 0.01 were calculated using the nonparametric Mann-Whitney test in comparison with miR-203 3xEV.</p><p>(F) Representative whole-mount ex&#x000a0;vivo GFP fluorescence microscopy images of lung metastases formed by all 16 combinations of SCC13 cell lines at day 88. Scale bar represents 3&#x000a0;mm.</p><p>(G) Kaplan-Meier plots for overall survival of 272 HNSCC patients from the TCGA cohort partitioned on the basis of LASP1, NUAK1, and SPARC RNAseq read counts; p values were calculated using the log rank Mantel-Cox test.</p><p>(H) LASP1, NUAK1, and SPARC mRNA expression was used to partition the GSE2379 cohort of 34 HNSCC patients; p values were calculated using the log rank Mantel-Cox test.</p></caption><graphic xlink:href="gr6"/></fig></floats-group></article>